Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)

NCT00355641 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00355641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00355641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
October 31, 2007
Enrollment
450 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome